Log in to search using one of your social media accounts:

 

Simcor (Simvastatin Niacin Extended Release) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 23, 2017 Category: Drugs & Pharmacology Source Type: news

Juvisync (Sitagliptin and Simvastatin) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 21, 2017 Category: Drugs & Pharmacology Source Type: news

Generic Vytorin to Hit U.S. Market (FREE)
By the Editors Clinicians may soon be able to prescribe generic Vytorin (ezetimibe/simvastatin) … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - April 28, 2017 Category: Primary Care Source Type: news

Dr Reddy's launches cholesterol lowering drug in US
The company has launched Ezetimibe and Simvastatin tablets in the strengths of 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg and 10 mg/80 mg in the US market. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - April 27, 2017 Category: Pharmaceuticals Source Type: news

Impax Announces FDA Approval and Launch of a Generic Version of Vytorin(R) (Ezetimibe/Simvastatin Tablets)
HAYWARD, Calif., April 26, 2017 -- (Healthcare Sales & Marketing Network) -- Impax Laboratories, Inc. (NASDAQ: IPXL), a specialty pharmaceutical company, today announced it has received final U.S. Food and Drug Administration (FDA) approval for a generic ... Biopharmaceuticals, Generics, FDA, Product Launch Impax Laboratories, Vytorin, ezetimibe, simvastatin (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 26, 2017 Category: Pharmaceuticals Source Type: news

Severe Rhabdomyolysis After Long-term Simvastatin Therapy Severe Rhabdomyolysis After Long-term Simvastatin Therapy
This case demonstrates that side effects of statins may occur even after a long, uneventful period of therapy, and highlights the need to be alert to potential drug-drug interactions.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 24, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Zocor (simvastatin) vs. Crestor (rosuvastatin)
Title: Zocor (simvastatin) vs. Crestor (rosuvastatin)Category: MedicationsCreated: 3/17/2017 12:00:00 AMLast Editorial Review: 3/17/2017 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - March 17, 2017 Category: Cardiology Source Type: news

lovastatin vs. simvastatin
Title: lovastatin vs. simvastatinCategory: MedicationsCreated: 3/9/2017 12:00:00 AMLast Editorial Review: 3/9/2017 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - March 9, 2017 Category: Cardiology Source Type: news

atorvastatin (Lipitor) vs. simvastatin (Zocor)
Title: atorvastatin (Lipitor) vs. simvastatin (Zocor)Category: MedicationsCreated: 3/2/2017 12:00:00 AMLast Editorial Review: 3/2/2017 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - March 2, 2017 Category: Cardiology Source Type: news

Know When Airway Discomfort is Indicative of Something Serious
Discussion Coughing is a normal response that protects the airway. Typically, when an irritant enters the airway, the body responds by drawing in a quick breath and then closes the glottis as the air is forced out. This increases the pressure in the airways, which helps move the irritant out of the air passages. As the air is forced out past the closed glottis, the recognizable coughing sound is made. A cough that persists for several days or increases in its intensity and frequency can be a sign of a serious condition. (Source: JEMS Patient Care)
Source: JEMS Patient Care - February 26, 2017 Category: Emergency Medicine Authors: Dennis Edgerly, EMT-P Tags: Airway & Respiratory Columns Source Type: news

Vytorin (Ezetimibe and Simvastatin) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 3, 2017 Category: Drugs & Pharmacology Source Type: news

Simvastatin's effects on survival and outcome in traumatic braininjury patients: a comparative study - Naghibi T, Madani S, Mazloomzadeh S, Dobakhti F.
BACKGROUND/AIM: Mortality and morbidity still remain high in patients with traumatic brain injuries. Understanding the role of new treatments in these patients is critical. The aim of this study was to determine the effect of simvastatin on survival and ou... (Source: SafetyLit)
Source: SafetyLit - September 19, 2016 Category: Global & Universal Tags: Alcohol and Other Drugs Source Type: news

simvastatin, Zocor
Title: simvastatin, ZocorCategory: MedicationsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 7/12/2016 12:00:00 AM (Source: MedicineNet Cholesterol General)
Source: MedicineNet Cholesterol General - July 12, 2016 Category: Cardiology Source Type: news

Zocor (simvastatin)
Title: Zocor (simvastatin) Category: Medications Created: 12/31/1997 12:00:00 AM Last Editorial Review: 7/12/2016 12:00:00 AM (Source: MedicineNet Cholesterol General)
Source: MedicineNet Cholesterol General - July 12, 2016 Category: Cardiology Source Type: news

Effect of cholesterol medicine on inflammatory diseases mapped
The cholesterol medicine simvastatin, which is one of the most commonly used pharmaceuticals in the world, also has a beneficial effect on the immune defense system with regard to diseases such as type 1 diabetes, multiple sclerosis and rheumatoid arthritis. Researchers have now explored why this is so, and their findings may result in improved treatment. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - July 7, 2016 Category: Science Source Type: news

Effect of cholesterol medicine on inflammatory diseases mapped
(Aarhus University) The cholesterol medicine simvastatin, which is one of the most commonly used pharmaceuticals in the world, also has a beneficial effect on the immune defence system with regard to diseases such as type 1 diabetes, multiple sclerosis and rheumatoid arthritis. Danish researchers have now explored why this is so, and their findings may result in improved treatment. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - July 7, 2016 Category: Biology Source Type: news

Simvastatin-Induced Cognitive Dysfunction: Two Case ReportsSimvastatin-Induced Cognitive Dysfunction: Two Case Reports
Might these patients' reversible memory and cognitive problems be attributable to their treatment with statins? Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 16, 2016 Category: Consumer Health News Tags: Internal Medicine Journal Article Source Type: news

Meet The Woman Who Launched A New Field Of Scientific Study
As a female chemical engineer, Frances Arnold was already a rarity. After all, only about 16 percent of chemical engineers are women. But now that she has become the first woman ever to win the prestigious Millennium Technology Prize — it was awarded in Helsinki, Finland, on May 24 — Arnold is truly one of a kind. And she knows that in addition to a big cash award (1 million euros, or about $1.3 million), the prize brings an opportunity to spotlight the gender gap in STEM (science, technology, engineering and math) careers and to be a role model for other women. "I hope that my getting this prize will high...
Source: Science - The Huffington Post - May 31, 2016 Category: Science Source Type: news

Simvastatin (Oral Suspension) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 9, 2016 Category: Drugs & Pharmacology Source Type: news

Some People Really Can't Take Statins For High Cholesterol, Scientists Prove
You can't write a story about the lifesaving benefits of the cholesterol-lowering drugs called statins without getting comments like this one, from reader Bill Hayman, on my story yesterday: I cannot take Crestor or Zetia or any form of statin drug! I can barely walk with any statin drug. My legs become painful and so weak, they feel like rubber. Several years ago, I used Lipitor and had four pancreatic attacks until I stopped the Lipitor. Or this, from reader James Leedy: People should be warned of side effects. Doctors should listen to patients . I have taken statins for several years. I had extreme muscle pains all t...
Source: Forbes.com Healthcare News - April 3, 2016 Category: Pharmaceuticals Authors: Matthew Herper Source Type: news

Ezetimibe/Simvastatin Post-Acute Coronary SyndromeEzetimibe/Simvastatin Post-Acute Coronary Syndrome
Can lipid-lowering therapy with ezetimibe plus simvastatin improve clinical outcomes among survivors of acute coronary syndromes? Journal of the American College of Cardiology (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - March 7, 2016 Category: Intensive Care Tags: Cardiology Journal Article Source Type: news

Merck Receives Complete Response Letter from the U.S. FDA for ZETIA® (ezetimibe) and VYTORIN® (ezetimibe and simvastatin)
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter regarding Merck's Supplemental New Drug Applications for ZETIA® and VYTORIN® for the reduction of the risk of cardiovascular events (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina, or need for revascularization) in patients with coronary heart disease. Language: ...
Source: Merck.com - Product News - February 15, 2016 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news

Merck Receives Complete Response Letter from the U.S. FDA for ZETIA ® (ezetimibe) and VYTORIN® (ezetimibe and simvastatin)
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--( BUSINESS WIRE )--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter regarding Merck's Supplemental New Drug Applications for ZETIA ® and VYTORIN® for the reduction of the risk of cardiovascular events (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina, or need for revascularization) in patients with coronary heart disease. Language: Englis...
Source: Merck.com - Product News - February 15, 2016 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news

The Jekyll and Hyde of Statins
By Drs. David Niesel and Norbert Herzog, Medical Discovery News Cholesterol-lowering drugs called statins are the most prescribed drug ever. About 30 percent of Americans are currently taking statins such as Crestor, Lipitor, Mevacor and Zocor. Overall, statins can be good thing, but as with all drugs, there are some negative effects. Statins lower cholesterol by inhibiting a protein called HMG-CoA reductase. Since high cholesterol levels are linked to heart disease, statins can reduce the risks of heart attack and stroke, two of the leading causes of death in the United States. Recent reports from the American Heart Assoc...
Source: Science - The Huffington Post - February 3, 2016 Category: Science Source Type: news

Impax Receives Tentative FDA Approval for Generic Version of Vytorin(R) (ezetimibe and simvastatin) Tablets, 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg and 10 mg/80 mg
HAYWARD, Calif., Feb. 2, 2016 -- (Healthcare Sales & Marketing Network) -- Impax Laboratories, Inc. (IPXL) today announced that Impax has received tentative approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application... Biopharmaceuticals, Generic, FDAImpax Laboratories, ezetimibe, simvastatin, Vytorin (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 2, 2016 Category: Pharmaceuticals Source Type: news

Could a cholesterol-lowering drug be a potential treatment for Parkinson's?
A clinical trial using cholesterol-lowering treatment Simvastatin in people living with Parkinson's is getting underway in centers across England -- with the hope that it could become one of a number of effective treatments available to treat Parkinson's. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - January 11, 2016 Category: Science Source Type: news

Could a cholesterol-lowering drug be a potential treatment for Parkinson's?
Cholesterol-lowering drug Simvastatin trialled as a potential neuroprotective treatment for Parkinson's. (Source: Parkinson's Disease News From Medical News Today)
Source: Parkinson's Disease News From Medical News Today - January 11, 2016 Category: Neurology Tags: Parkinson's Disease Source Type: news

Celebratory Excess Drinking Causes Atrial Arrhythmias
It's New Year's Eve and the ball is about to drop. You and your partner respond to a party that's been going for several hours to care for a person who's dizzy. Making your way through the streamers and horns, you're ushered to a back bedroom where you're introduced to Uncle Bill. Uncle Bill is 52 years old and lying on the bed. He looks up at you and says, "Something's not right, boys." You reach to feel his pulse and ask what he means by his statement. You note the smell of alcohol on his breath as he tells you the evening was going great until he suddenly felt faint and his heart began to race. He sat down and...
Source: JEMS Patient Care - December 22, 2015 Category: Emergency Medicine Authors: Dennis Edgerly, EMT-P Tags: Cardiac & Resuscitation Toxicology Columns Source Type: news

Merck Statement on FDA Advisory Committee Meeting on IMPROVE-IT Study with VYTORIN® (ezetimibe and simvastatin)
Dateline City: KENILWORTH, N.J. Merck (NYSE: MRK), known as MSD outside the United States and Canada, issued today the following statement after the conclusion of a meeting of the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) to discuss the results of IMPROVE-IT, an investigational study comparing treatment with VYTORIN® (ezetimibe and simvastatin) to treatment with simvastatin alone in more than 18,000 patients presenting with acute coronary syndromes. Language: English read more (Source: Merck.com - Corporate News)
Source: Merck.com - Corporate News - December 14, 2015 Category: Pharmaceuticals Tags: Corporate News Latest News Source Type: news

New Analyses from the IMPROVE-IT Study with VYTORIN® (ezetimibe and simvastatin)
Dateline City: KENILWORTH, N.J. Further Analyses on the Long-Term Safety and Efficacy of VYTORIN® from the IMPROVE-IT Study Presented at the European Society of Cardiology (ESC) Meeting KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD in the United States and Canada, today announced results from new analyses from the IMPROVE-IT study. “IMPROVE-IT presents us with the opportunity to look at cardiovascular outcomes data for patients treated with the combination of simvastatin and ezetimibe (VYTORIN) and...
Source: Merck.com - Research and Development News - September 1, 2015 Category: Pharmaceuticals Tags: Research and Development News Source Type: news

New Analyses from the IMPROVE-IT Outcomes Study of VYTORIN® (ezetimibe and simvastatin) and the TECOS Cardiovascular Safety Trial of JANUVIA® (sitagliptin) Will Be Presented at the European Society of Cardiology Congress
Dateline City: KENILWORTH, N.J. Additional Real-World Analyses from DYSIS and DYSIS II Assessing the Treatment of Dyslipidemia to be Presented KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that new analyses from the investigational IMPROVE-IT (IMProved Reduction of Outcomes: VYTORIN Efficacy International Trial) study of VYTORIN® (ezetimibe and simvastatin), the TECOS (Trial Evaluating Cardiovascular Outcomes with Sitagliptin) cardiovascular safety trial ...
Source: Merck.com - Product News - August 20, 2015 Category: Drugs & Pharmacology Tags: Prescription Medicine News Research and Development News Corporate News Latest News Source Type: news

Studies support broader use of cholesterol-lowering statins
The latest guidelines used to determine who should take a cholesterol-lowering statin to prevent heart disease appear to be more accurate and cost-efficient than the previous guidelines. That’s according to two studies led by Harvard researchers, both published in this week’s Journal of the American Medical Association. For many years, the main deciding factor in who needed to take a statin was the level of an individual’s harmful low-density lipoprotein cholesterol (LDL). Updated guidelines published in 2013 by the American College of Cardiology and the American Heart Association moved away from LDL and ...
Source: New Harvard Health Information - July 16, 2015 Category: Consumer Health News Authors: Julie Corliss Tags: Drugs and Supplements cholesterol high cholesterol statins Source Type: news

Studies: Millions Could Benefit By Taking Cholesterol-Lowering Medications
BOSTON (CBS) — Millions more Americans could benefit from treatment with popular cholesterol-lowering medications, according to two new studies. Nearly half of adults ages 40-to-75 might be eligible to take them. Heart disease is still the number one killer of American men and women and cholesterol-lowering statins, like atorvastatin (Lipitor) and simvastatin (Zocor), have been shown to reduce heart disease in people at risk. Before, doctors would treat patients primarily based on their cholesterol levels, but a couple of years ago, leading cardiologists urged doctors to treat patients based on their overall risk inc...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - July 15, 2015 Category: Consumer Health News Authors: mouellette2015 Tags: Health Healthwatch Heart Health Local News Seen On WBZ-TV Syndicated Local Watch Listen Atorvastatin Dr. Mallika Marshall Health News Heart Disease Lipitor National Institutes Of Health Simvastatin Statins Zocor Source Type: news

400-Pound Patient Impales Himself Twice Falling on Magazine Rack
Engine 1, an ALS engine company staffed with one paramedic and two EMTs, is dispatched to assist police with a welfare check. On arrival, the crew finds a small, one-story house with the doors locked. After knocking on the door, a male voice is heard yelling for help. The door is immediately forced open and the crew finds a conscious obese male, lying supine on the floor, impaled by two wooden dowels of a magazine rack. The dowels are penetrating the posterior right buttock and continue through to his lower abdomen and pelvis. The officer radios dispatch and requests Truck 1 and Rescue 1 be dispatched emergent to the scene...
Source: JEMS Patient Care - July 14, 2015 Category: Emergency Medicine Authors: Matthew Kunkle, EMT PM, CCP Tags: Case of the Month Patient Assessment Special Patients Trauma Special Challenges Bleeding Patient Care Burns & Soft Tissue Trauma Special Topics Source Type: news

400-Pound Patient Impales Himself Twice Falling on Magazine Rack
Engine 1, an ALS engine company staffed with one paramedic and two EMTs, is dispatched to assist police with a welfare check. On arrival, the crew finds a small, one-story house with the doors locked. After knocking on the door, a male voice is heard yelling for help. The door is immediately forced open and the crew finds a conscious obese male, lying supine on the floor, impaled by two wooden dowels of a magazine rack. The dowels are penetrating the posterior right buttock and continue through to his lower abdomen and pelvis. The officer radios dispatch and requests Truck 1 and Rescue 1 be dispatched emergent to the scene...
Source: JEMS Special Topics - July 14, 2015 Category: Emergency Medicine Authors: Matthew Kunkle, EMT PM, CCP Tags: Case of the Month Patient Assessment Special Patients Trauma Special Challenges Bleeding Patient Care Burns & Soft Tissue Trauma Special Topics Source Type: news

Some Improvement in Post-ACS Outcomes with Adjunctive Ezetimibe (FREE)
By Harlan M. Krumholz, MD, SM Dr. Krumholz is Editor-in-Chief of NEJM Journal Watch Cardiology, from which this story was adapted. See full coverage at the link below.Ezetimibe plus simvastatin is associated with better outcomes at 7 years than statin monotherapy, according to a New England … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - June 4, 2015 Category: Primary Care Source Type: news

Results from Investigational IMPROVE-IT Study of VYTORIN® (ezetimibe and simvastatin) Published in the New England Journal of Medicine
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the New England Journal of Medicine published the results of the IMPROVE-IT trial, an investigational study comparing treatment with VYTORIN® (ezetimibe and simvastatin) to treatment with simvastatin alone in more than 18,000 patients presenting with acute coronary syndromes. Language: English Contact: MerckMedia:Pamela Eisele, (267) 30...
Source: Merck.com - Product News - June 3, 2015 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news

Does Preop Statin Help Survival in CABG?
(MedPage Today) -- Study suggested simvastatin may help but other preop heart drugs weren't useful. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - June 1, 2015 Category: Cardiology Source Type: news

Cholesterol – the super-stealthy invisible illness
Sourced from The Hysterectomy Association: Hysterectomy Association - Hysterectomy Association - hysterectomy, menopause and hormone replacement therapy (hrt) information and support for women. As far as invisible illnesses go, they don’t come much stealthier than high cholesterol. It’s easily ignored because it builds up gradually, often showing no symptoms whatsoever. A person with high or increasing cholesterol levels will most likely feel perfectly healthy. It’s a scary though that the first sign of high cholesterol may be a heart attack or stroke – and could even prove fatal! Fortunately, medic...
Source: The Hysterectomy Association - March 26, 2015 Category: OBGYN Authors: Linda Parkinson-Hardman Tags: Health Conditions cholesterol invisible illness Source Type: news

Micro Labs recalls 54,096 bottles of cholesterol drug in US
Micro Labs is voluntarily recalling 54,096 bottles of Simvastatin Tablets, a drug for lowering cholesterol, in the US market for failing to meet specifications. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - March 19, 2015 Category: Pharmaceuticals Source Type: news

New Analysis from Investigational IMPROVE-IT Study Shows VYTORIN® (ezetimibe/simvastatin) Reduced Total (Initial and Recurrent) Cardiovascular Events More than Simvastatin Alone in Patients Presenting with Acute Coronary Syndromes
Dateline City: SAN DIEGO SAN DIEGO--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from a pre-specified exploratory analysis of the investigational IMPROVE-IT study of more than 18,000 patients presenting with acute coronary syndromes. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orMichael Close, 267-305-1211orInvestors:Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK...
Source: Merck.com - Product News - March 16, 2015 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news

A New Class Of Experimental Cholesterol Drugs Are Outperforming Traditional Statins
SAN DIEGO (AP) — New research boosts hope that a highly anticipated, experimental class of cholesterol drugs can greatly lower the risk for heart attacks, death and other heart-related problems. The government will decide this summer whether to allow two of these drugs on the market. People taking one of these drugs had half the risk of dying or suffering a heart problem compared to others who were given usual care — typically one of the statin drugs such as Lipitor or Zocor, doctors found. Many people cannot tolerate statins or get enough help from them, so new medicines are badly needed. The results are &qu...
Source: Science - The Huffington Post - March 16, 2015 Category: Science Source Type: news

New Data from IMPROVE-IT Study of VYTORIN® (ezetimibe/simvastatin) and TRA 2ºP TIMI 50 Study of ZONTIVITY® (vorapaxar) to be Presented at American College of Cardiology Scientific Sessions
Dateline City: KENILWORTH, N.J. Investigational data from IMPROVE-IT to be announced in Featured Clinical Research Session II KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that new data from two trials of the company’s cardiovascular medicines will be presented at the 2015 American College of Cardiology Annual Scientific Sessions (ACC.15), March 14-16 in San Diego. Language: English Contact: ...
Source: Merck.com - Product News - February 25, 2015 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news

Do you take medication for high cholesterol?
Sourced from The Hysterectomy Association: Hysterectomy Association - Hysterectomy Association - hysterectomy, menopause and hormone replacement therapy (hrt) information and support for women. 6 out of every 10 people in the UK have raised cholesterol levels. Over time, cholesterol can build up in the arteries – so without treatment, high cholesterol levels can lead to serious health issues, including heart attacks, strokes and angina. In the UK alone, 6 – 7 million people are taking prescribed medicines called statins to help lower their cholesterol levels. Some commonly prescribed statins in the UK include s...
Source: The Hysterectomy Association - February 13, 2015 Category: OBGYN Authors: Linda Parkinson-Hardman Tags: Latest News Source Type: news

VYTORIN® (ezetimibe/simvastatin) Significantly Reduced Cardiovascular Events More than Simvastatin Alone in Patients Presenting with Acute Coronary Syndromes in the Investigational IMPROVE-IT Study
Dateline City: CHICAGO CHICAGO--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the investigational IMPROVE-IT study met its primary and all secondary composite efficacy endpoints. Language: English Contact: MerckMedia Contact:Pam Eisele, 267-305-3558orInvestor Contact:Joe Romanelli, 908-423-5185 Ticker Slug: Ticker: MRK Exchange: NYSE read more (Source: Merck.com - Product News)
Source: Merck.com - Product News - November 17, 2014 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news

Common cholesterol-fighting drug may prevent hysterectomies in women with uterine fibroids
The cholesterol-lowering drug simvastatin inhibits the growth of human uterine fibroid tumors, researchers have discovered for the first time. Statins, such as simvastatin, are commonly prescribed to lower high cholesterol levels. Beyond these well-known cholesterol-lowering abilities, statins also combat certain tumors. Statins have previously been shown to have anti-tumor effects on breast, ovarian, prostate, colon, leukemia and lung cancers. The effect of statins on uterine fibroids was unknown. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - November 13, 2014 Category: Science Source Type: news

Common cholesterol-fighting drug may prevent hysterectomies in women with uterine fibroids
(University of Texas Medical Branch at Galveston) Researchers at the University of Texas Medical Branch at Galveston, in collaboration with The University of Texas Health Science Center at Houston, Baylor College of Medicine and the Georgia Regents University, report for the first time that the cholesterol-lowering drug simvastatin inhibits the growth of human uterine fibroid tumors. These new data are published online and scheduled to appear in the January print edition of the Journal of Biological Chemistry. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 13, 2014 Category: Global & Universal Source Type: news

Repurposing statins
Neurologists and the MS Society have written to the Telegraph in support of a bill currently before parliament that would make it easier to re-licensed existing drugs for new conditions. Coverage focuses on simvastatin which has been studied in secondary progressive MS, though more research is still required. Daily Telegraph Daily Mail Statins - A to Z of MS (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - November 4, 2014 Category: Neurology Source Type: news